To the full analysis
Stryker stock: growth
SYKStryker reported $25.12B in revenue for fiscal 2025, up 11.2% on the prior year, up 11.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
8.4%
per year from 2006 to 2025, per share 8.8%
Earnings (Annual rate)
7.8%
per year from 2006 to 2025, per share 8.2%
Free cash flow (Annual rate)
10.4%
per year from 2006 to 2025, per share 10.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 11.8% | 9.7% | 8.4% |
| Revenue per share | 11.4% | 9.5% | 8.8% |
| Earnings | 15.2% | 8.5% | 7.8% |
| Earnings per share | 14.8% | 8.3% | 8.2% |
| Free cash flow | 9.0% | 21.1% | 10.4% |
| Free cash flow per share | 8.6% | 21.0% | 10.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $5.41B | $777.7M | $649.8M |
| 2007 | $6B | $1.02B | $840.6M |
| 2008 | $6.72B | $1.15B | $1.02B |
| 2009 | $6.72B | $1.11B | $1.33B |
| 2010 | $7.32B | $1.27B | $1.37B |
| 2011 | $8.31B | $1.35B | $1.21B |
| 2012 | $8.66B | $1.3B | $1.45B |
| 2013 | $9.02B | $1.01B | $1.69B |
| 2014 | $9.68B | $515M | $1.55B |
| 2015 | $9.95B | $1.44B | $629M |
| 2016 | $11.33B | $1.65B | $1.43B |
| 2017 | $12.44B | $1.02B | $961M |
| 2018 | $13.6B | $3.55B | $2.04B |
| 2019 | $14.88B | $2.08B | $1.54B |
| 2020 | $14.35B | $1.6B | $2.79B |
| 2021 | $17.11B | $1.99B | $2.74B |
| 2022 | $18.45B | $2.36B | $2.04B |
| 2023 | $20.5B | $3.17B | $3.14B |
| 2024 | $22.6B | $2.99B | $3.49B |
| 2025 | $25.12B | $3.25B | $4.28B |
Revenue by segment
How Stryker Corporation makes its money and how that has shifted. Names are as the company reports them.
- MedSurg62%
- Orthopaedics38%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| MedSurg | $13.52B | $15.65B | 62.3% |
| Orthopaedics | $9.08B | $9.47B | 37.7% |
| Total revenue | $22.6B | $25.12B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.